Maxim Group set a $4.00 price target on AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) in a research note released on Thursday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
Other research analysts have also issued reports about the stock. HC Wainwright set a $3.00 price target on shares of AEterna Zentaris and gave the company a buy rating in a research report on Wednesday, November 29th. ValuEngine raised shares of AEterna Zentaris from a strong sell rating to a sell rating in a research report on Friday, September 1st. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. AEterna Zentaris currently has an average rating of Hold and an average target price of $4.33.
AEterna Zentaris (NASDAQ:AEZS) opened at $2.45 on Thursday. AEterna Zentaris has a 12-month low of $0.78 and a 12-month high of $4.25. The firm has a market cap of $44.39, a PE ratio of -1.35 and a beta of 0.87.
AEterna Zentaris Company Profile
Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.
What are top analysts saying about AEterna Zentaris? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AEterna Zentaris and related companies.